PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Health

Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial

The ZEUS clinical trial found that the anti-inflammatory drug ziltivekimab did not reduce major cardiovascular events in high-risk patients.

8sources
9articles
6velocity
+127%since first seen
9d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Heart researchers at the American Heart Association annual meeting in Chicago unpacked the neutral findings from ZEUS, a major anti-inflammatory clinical trial. According to MedPage Today, the global phase 3 trial tested ziltivekimab, a monoclonal antibody designed to target interleukin-6 (IL-6). While the treatment substantially reduced inflammatory markers, including free IL-6 and high-sensitivity C-reactive protein (CRP), it failed to reduce the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Paul M. Ridker, MD, of Harvard Medical School and Mass General Brigham Hospital reported that over a median follow-up of 33 months, primary endpoint events occurred in 561 patients in the ziltivekimab group and 565 patients in the placebo group. Medical Xpress noted that ZEUS enrolled patients with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation who were a decade older, had significant kidney disease, and often suffered from longstanding diabetes and heart failure compared to populations in earlier successful trials like CANTOS. Ridker explained that in such patients with advanced disease, "the horse may already have been out of the barn," suggesting that targeting a downstream molecule like IL-6 may have been applied to the wrong, highly advanced patient population. BioSpace reported that following the topline results released in July 2026, Novo Nordisk ended several studies of ziltivekimab, including HERMES and ATHENA, but allowed the Phase 3 ARTEMIS trial in acute settings to continue. Discussant Priscilla Hsue, MD, questioned whether the drug was given too late or if targeting the ligand rather than the receptor was the wrong strategy. Despite the neutral trial outcome, researchers emphasized that inflammation remains a critical treatment target. MedPage Today and Medical Xpress reported that clinicians can still utilize lifestyle measures and available drugs such as statins, GLP-1 receptor agonists, and colchicine, which has been shown to reduce cardiovascular risk.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 8d ago.

Quick answers

Did ziltivekimab lower inflammatory markers in the ZEUS trial?

Yes. MedPage Today reported that ziltivekimab produced substantial reductions in free interleukin-6 (IL-6) and high-sensitivity C-reactive protein (CRP).

What were the primary endpoints of the ZEUS trial?

According to MedPage Today, the primary composite endpoint included death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

Which ongoing ziltivekimab trial was allowed to continue after ZEUS?

BioSpace and MedPage Today reported that the Phase 3 ARTEMIS trial in acute settings is continuing.

Coverage (9)

Topics

Related trends

\n \n \n \n \n \n \n